Key clinical-trial evidence for interferon for melanoma

Author: Anoma Ranaweera B.V. Sc; PhD (Clinical Biochemistry, University of Liverpool, UK). Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, December 2015.

Three types of interferon-alpha are commercially available: peginterferon alfa-2b (Sylatron®; Schering-Plough Corporation, Madison New Jersey [NJ], USA), interferon alfa-2b (Intron® A; Schering-Plough Corporation, Madison NJ , USA), and interferon alfa-2a (Roferon&reg-A;, Hoffmann-La Roche, Madison, NJ, USA); each differs minimally in their amino-acid sequence.

All preparations are available in New Zealand except peginterferon alfa-2b.

Peginterferon alfa-2b (Sylatron®)

Peginterferon. Drug-related adverse reactions in >5% of patients
Sylatron® (n = 629) Observation (n = 628)
Adverse reaction All grades (%) All Grades (%)
General disorders and administration site conditions
Fatigue 94 41
Pyrexia 75 9
Chills 63 6
Injection site reactions 62 0
Gastrointestinal disorders
Diarrhoea 37 8
Nausea 64 11
Vomiting 26 4
Respiratory disorders
Dyspnoea 6 2
Cough 5 2
Skin disorders
Rash 36 4
alopecia 34 1
Musculoskeletal disorders
Arthralgia 51 22
Myalgia 68 23
Nervous system disorders
Headache 70 19
Dizziness 35 11
Liver function
Increased AST 77 26

Interferon alfa-2b (Intron®A)

ECOG 1684

ECOG 1690

Interferon alfa-2a (Roferon® -A)

French Melanoma Cooperative Group Trial

Austrian Melanoma Cooperative Group Trial

Future directions

Related information

Make a donation

Donate Today

Help us to update and maintain DermNet New Zealand

Thanks to our volunteers

Watch Dr Amanda Oakley's Lifetime Service - TechSoup 2017 award video

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter